The pea-sized device is implanted behind the iris of one eye. The FDA-approved procedure does not reverse AMD, but may improve vision for those who are legally blind from the condition.
Candidates for the surgery are 75 and older with irreversible end-stage AMD and are no longer candidates for drug-based treatment. They must have vision ranging between 10/160 and 20/800, and may not have undergone cataract surgery in the eye in which the device would be implanted.
More Articles on Eye Surgery:
Glaucoma Drug Latanoprostene Bunod Enters Trial Phase 3
10 Milestones for Ambulatory Surgery Centers
3 Reasons LASIK Surgery is More Popular in the Winter
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
